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Prostaglandin (PG) D2 is well known as a mediator of inflammation. Hematopoietic PGD synthase (HPGDS) is responsible for the
production of PGD2 involved in inflammatory responses. Microglial activation and astrogliosis are commonly observed during neuroin-
flammation, including that which occurs during demyelination. Using the genetic demyelination mouse twitcher, a model of human
Krabbe’s disease, we discovered that activated microglia expressed HPGDS and activated astrocytes expressed the DP1 receptor for PGD2
in the brain of these mice. Cultured microglia actively produced PGD2 by the action of HPGDS. Cultured astrocytes expressed two types of
PGD2 receptor, DP1 and DP2 , and showed enhanced GFAP production after stimulation of either receptor with its respective agonist.
These results suggest that PGD2 plays an important role in microglia/astrocyte interaction. We demonstrated that the blockade of the
HPGDS/PGD2 /DP signaling pathway using HPGDS- or DP1-null twitcher mice, and twitcher mice treated with an HPGDS inhibitor,
HQL-79 (4-benzhydryloxy-1-[3-(1H-tetrazol-5-yl)-propyl]piperidine), resulted in remarkable suppression of astrogliosis and demyeli-
nation, as well as a reduction in twitching and spasticity. Furthermore, we found that the degree of oligodendroglial apoptosis was also
reduced in HPGDS-null and HQL-79-treated twitcher mice. These results suggest that PGD2 is the key neuroinflammatory molecule that
heightens the pathological response to demyelination in twitcher mice.
Introduction
Prostaglandin (PG) D2 is a well known mediator of inflamma-
tion. It augments vascular permeability (Flower et al., 1976), che-
motaxis (Hirai et al., 2001), and antigen presentation (Herve et
al., 2003), inhibits platelet aggregation (Whittle et al., 1978), and
induces vasodilatation and bronchoconstriction (Wasserman et
al., 1980). Hematopoietic PGD synthase (HPGDS) is responsible
for the production of PGD2, including that linked to immune and
inflammatory responses (Kanaoka and Urade, 2003). HPGDS is
expressed in human Th2 lymphocytes (Tanaka et al., 2000),
antigen-presenting cells (Urade et al., 1989), mast cells (Urade et
al., 1990), and microglia (Mohri et al., 2003).
Microglial activation and astrogliosis are commonly observed
during the neuroinflammation associated with brain injury, in-
fection, and neurodegenerative diseases. However, the molecular
mechanism underlying microglial activation and astrogliosis is
still poorly understood. The twitcher mouse (C57BL/6J-GALCtwi:
GALCtwi/twi) is an authentic animal model of human globoid cell
leukodystrophy (Krabbe’s disease) resulting from the deficiency
of galactosylceramidase (Duchen et al., 1980; Kobayashi et al.,
1980). In this model, initial myelination progresses normally
(Nagara et al., 1982), but then demyelination begins as a result of
the apoptosis of oligodendrocytes (OLs) after postnatal day 30
(P30) (Taniike et al., 1999). Demyelination in twitcher progresses
in an orderly manner (Taniike and Suzuki, 1994) and is always
accompanied by both microglial activation and astrogliosis
throughout the brain (Ohno et al., 1993b). Interestingly, the
pathological features of GALCtwi/twi have many characteristics
in common with multiple sclerosis (MS). For example, in both
conditions, major histocompatibility complex (MHC) mole-
cules contribute to disease progression (Ohno et al., 1993a;
Matsushima et al., 1994, Taniike et al., 1997). The absence of
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MHC class II molecules reduces CNS demyelination and
microglial/macrophage infiltration in the twitcher brain (Mat-
sushima et al., 1994). It has also been reported that there is
expression of proinflammatory molecules, such as interleu-
kin-6 (IL-6), tumor necrosis factor  (TNF) (LeVine and
Brown, 1997), monocyte chemoattractant protein-1, interfer-
on-induced protein-10, macrophage inflammatory pro-
tein-1 (MIP-1), MIP-1, and RANTES (regulated on acti-
vation normal T-cell expressed and secreted) (Wu et al., 2000)
in twitcher. Furthermore, we recently reported that TNF ex-
pression increased with the progression of demyelination in
twitcher and that a TNF inhibitor suppresses such demyeli-
nation (Kagitani-Shimono et al., 2005). These correlations
make the twitcher mice a model system for investigating the
molecular events of neuroinflammation in demyelinating
diseases.
In the present study, we found that HPGDS expression was pro-
gressively upregulated in activated microglia in the GALCtwi/twi
brain. This upregulation was accompanied by the expression of the
PGD2 receptor DP1 in hypertrophic astrocytes located close to
HPGDS-positive (HPGDS) microglia. Using glial cells in primary
culture, we demonstrated that activated microglia produced a large
amount of PGD2 synthesized by HPGDS and that astrocytes ex-
pressed both DP1 and DP2 receptors and were activated by PGD2.
Using HPGDS- or DP1-null GALC
twi/twi mice and GALCtwi/twi mice
treated with an HPGDS-inhibitor, we also found that blockade of the
HPGDS/PGD2/DP1 signaling pathway resulted in the suppression of
astrogliosis and apoptosis of OLs as well as in that of demyelination.
This is the first example of a PGD2-mediated microglia/astrocyte
interaction that enhances neuroinflammation and demyelination,
and our findings may cast new light on strategies for the treatment of
Krabbe’s disease.
Materials and Methods
Mice. All animal experiments were performed in accordance with the
Japanese Law for the Protection of Experimental Animals and con-
formed to the regulations issued by the National Institutes of Health and
the Society for Neuroscience. GALCtwi/ mice were originally purchased
from The Jackson Laboratory (Bar Harbor, ME), and the mutation was
maintained by interbreeding of known heterozygous mice. DNA was
extracted from clipped tails for the detection of wild-type or mutant
alleles of GALC, which was done with primers gtwf2 (5-
CAGTCATTCAGAAAGTCTTCC-3) and gtwr3 (5-GCCCACTGTCT-
TCAGGTGATA-3; mismatch primer). The PCR fragment of 237 bp of
the normal allele was not digested by EcoRV, whereas that of the mutant
allele was, resulting in a 217 bp fragment.
HPGDS/ and DP1
/ mice were generated by standard gene-
targeting technology with mouse embryonic stem cells derived from the
129 strain and backcrossed to the inbred C57BL/6J strain 15 times. The
former strain was created by the Osaka Bioscience Institute and Japan
Tobacco Inc. Pharmaceutical Frontier Research Laboratories, and the
latter was created at Kyoto University (Matsuoka et al., 2000). Neither
strain exhibits any adverse neurological symptomatology. For genotyp-
ing of HPGDS, primer FW1 (5-GAGTTGCTGCATCTGACCTTTC-3)
and RV1 (5-TAGCGAATAATTTCGGCTCTTCC-3) were used to de-
tect the wild-type allele, and H-FW1 (AAGATCTGTCTTGTTG-
CGTACGCT-3) and NeoR8 (5-GTCCAGATCATCCTGATCGAC-5)
were used for that of the targeted allele. For the detection of wild-type or
mutant alleles of DP1, primer DP1 (5-TCGGTCTTTTATGTG-
CTCGTG-3) or Neo1 (5-CCCGTGATATTGCTGAAGAGC-3) was
used together with DP2 (5-GAATCATCTGGATGAAACACC-3).
Double-mutant mice (HPGDS/GALCtwi/twi or DP1
/GALCtwi/twi)
were generated by mating HPGDS/ C57BL/6J (HPGDS/GALC/)
or DP1
/ C57BL/6J (DP1
/GALC/) offspring with HPGDS/
DP1
/GALCtwi/. The F1 litters (HPGDS/GALCtwi/ and DP1
/




These three types of GALCtwi/twi male mice were used for analysis. The
frequency of each genotype in all generations conformed to Mendelian
inheritance patterns.
HQL-79 (4-benzhydryloxy-1-[3-(1 H-tetrazol-5-yl)-propyl]piperi-
dine) (Aritake et al., 2006), an inhibitor of HPGDS, was purchased from
Cayman Chemical (Ann Arbor, MI). GALCtwi/twi received a daily subcu-
taneous injection of HQL-79 (suspended in 0.5% methylcellulose; 50
mg  kg 1  d 1) from P25 to P45. As a control, the same volume of
vehicle was injected into GALCtwi/twi during the same period.
Materials. Rabbit polyclonal (0.1 g/ml) and rat monoclonal (0.2 g/
ml) anti-mouse HPGDS antibodies were raised and purified at Osaka
Bioscience Institute (Mohri et al., 2003). The preabsorbed antibody was
prepared by incubation of the polyclonal antibody with an excess
amount of purified mouse HPGDS recombinantly expressed in Esche-
richia coli (Kanaoka et al., 2000). Guinea pig anti-DP1 antiserum (1:30)
was also raised at Osaka Bioscience Institute (Mizoguchi et al., 2001). The
other antibodies used were as follow: rabbit polyclonal antibodies against
-class glutathione S-transferase (-GST) (1:1000; Biotrin Interna-
tional, Dublin, Ireland), NG2 (1:200; Chemicon, Temecula, CA), myelin
basic protein (MBP) (1:5000; DakoCytomation, Glostrup, Denmark),
cow glial fibrillary acidic protein (GFAP) (1:5000; DakoCytomation),
and rat monoclonal anti-mouse F4/80 antibody (1:500; Serotec, Oxford,
UK). Biotinylated Ricinus communis-agglutinin-1 (RCA-1) was pur-
chased from Vector Laboratories (Burlingame, CA) (50 g/ml).
Measurement of HPGDS activity and PGD2 content in the brain.
HPGDS activity in the brains of GALC/ and GALCtwi/twi mice at P39
(n  4 each) was determined by using 40 M [1- 14C]PGH2 in the pres-
ence of 1 mM glutathione, as described previously (Urade et al., 1985).
Protein concentrations were determined with bicinchoninic acid reagent
(Pierce, Rockford, IL), using bovine serum albumin as a standard as per
the protocol of the manufacturer. Quantities of PGD2, PGE2, and PGF2
in fresh-frozen brains of GALC/ and GALCtwi/twi mice decapitated at
P39 (n  6 each) were determined by enzyme immunoassays as de-
scribed previously (Ram et al., 1997).
Northern blotting and quantitative PCR. Total RNA was extracted from
mouse cerebrum and cerebellum by the guanidinium thiocyanate-
phenol-chloroform method using ISOGEN (Nippon Gene, Tokyo, Ja-
pan). Total RNA (10 g) was electrophoresed in an agarose gel, trans-
ferred to Zeta Probe nylon membranes (Bio-Rad, Hercules, CA), and
hybridized with 32P-labeled cDNA probes specific for mouse GFAP and
glyceraldehyde-3-phosphate dehydrogenase (G3PDH). The blots were
visualized by autoradiography with Eastman Kodak (Rochester, NY)
XAR-5 film and an intensifying screen. The relative amount of each
transcript was estimated by quantifying the associated radioactivity with
a BAS-2000 (Fuji Film, Tokyo, Japan).
Quantitative PCR analysis of the amounts of mRNAs for HPGDS,
DP1, DP2, peroxisome proliferator activated receptor  (PPAR), GFAP,
and G3PDH was performed by using a LightCycler amplification and
detection system (Roche Diagnostics, Indianapolis, IN) as described be-
low. Each sample of total RNA (2 g) was reverse transcribed at 50°C for
30 min into single-stranded cDNA in a reaction mixture containing 20 U
of RNase inhibitor, 1 RNA PCR buffer, 1 mM dNTP mixture, 2.5 M
random primer, and 5 U of avian myeloblastosis virus reverse transcrip-
tase (Takara Biomedicals, Kyoto, Japan). The sequence-specific primers
used were as follow: HPGDS forward primer, 5-GAATAGAACAAGCT-
GACTGGC-3; HPGDS reverse primer, 5-AGCCAAATCTGTGTTTT-
TGG-3; DP1 forward primer, 5-TTTGGGAAGTTCGTGCAGTACT-
3; DP1 reverse primer, 5-GCCATGAGGCTGGAGTAGA-3; DP2
forward primer, 5-TGGCCTTCTTCAACAGCGT-3; DP2 reverse
primer, 5-ACGCAGTTGGGGAATTCG-3; PPAR forward primer,
5-GGAGATCTCCAGTGATATCGACCA-3; PPAR reverse primer,
5-ACGGCTTCTACGGATCGAAACT-3; GFAP forward primer, 5-
TTCCTGGAACAGCAAAACAAGGCGCT-3; GFAP reverse primer, 5-
CTGTCTATACGCAGCCAGGTTGTTCTC-3; inducible nitric oxide
synthase (iNOS) forward primer, 5-CAGCAATATAGGCTCATCCA-
GAG-3; iNOS reverse primer, 5-GTGGTGTAGGACAATCCA-
CAACT-5; G3PDH forward primer, 5-TGAACGGGAAGCTCAC-
TGG-3; and G3PDH reverse primer, 5-TCCACCACCCTGTTGCT-3.
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The constructs used to create a standard curve were made by cloning each
amplified fragment into the HindIII site of a pGEM vector (Promega,
Madison, WI). The number of copies was calculated by plotting a dilu-
tion series on this standard curve in each PCR experiment. The PCR
mixture contained Taq polymerase, X LightCycle DNA master SYBR
Green (Roche Diagnostics) reaction buffer, 3 mM MgCl2, and 12.5 pmol
of each primer. After PCR had been performed for 40 cycles of denatur-
ation (95°C for 1 s), annealing (57°C for 5 s), and enzymatic chain exten-
sion (72°C for 10 s), the products for HPGDS, DP1, DP2, PPAR, GFAP,
and G3PDH were detected at 87, 83, 83, 91, 87, and 84°C, respectively. All
PCR products were visualized under UV light after electrophoresis in an
agarose gel containing ethidium bromide and were subsequently se-
quenced to verify that only the specific polymerization from the intended
mRNA had occurred.
Western blotting analysis. The brains were homogenized in 3 vol by
weight of PBS. After centrifugation at 16,000  g for 20 min, the super-
natant and the precipitate were used in Western blotting for HPGDS and
MBP, respectively. Protein was electrophoresed in 15/25% SDS-
polyacrylamide gradient gel (Daiichi, Tokyo, Japan), and, subsequently,
the separated proteins were electrophoretically transferred to an Immo-
bilon polyvinylidene difluoride membrane (Millipore, Bedford, MA).
The membrane was reacted with the rabbit polyclonal anti-HPGDS an-
tibody (0.5 g/ml) or anti--actin polyclonal antibody (1:1000; Abcam,
Cambridge, UK) at 4°C overnight. After alkaline phosphatase-
conjugated anti-rabbit IgG (1:3000) had been applied, HPGDS and MBP
were detected by using a 5-bromo-4-chlor-indolyl-phosphate/nitroblue-
tetrazolium-chloride developing kit (Amersham Bioscience, Uppsala,
Sweden).
Immunocytochemistry. GALCtwi/twi and GALC/ mice at P20, P30,
P40, and P45 were used for immunocytochemical analysis. Under deep
ether anesthesia, the mice were perfused via the heart with physiological
saline, followed by 4% paraformaldehyde in 0.1 M sodium phosphate, pH
7.4, for 10 min. The brains were removed and postfixed in the same
fixative overnight. After a coronal slice had been taken, they were rou-
tinely embedded in paraffin. Additionally, two each of the GALCtwi/twi
and GALC/ mice at P45 were perfused with physiological saline
only and processed for the preparation of fresh-frozen sections. Both
paraffin and frozen sections (5 m thick) were mounted on
3-aminopropyl-triethoxysilane-coated slides.
HPGDS immunostaining was performed as described previously
(Mohri et al., 2003). Rabbit anti-mouse HPGDS antibody was applied
followed by biotinylated anti-rabbit IgG and avidin-biotin complex
(ABC) from an ABC Elite kit (Vector Laboratories). Immunoreactivity
was visualized by the addition of diaminobenzidine hydrochloride
(DAB) (Dotite, Kumamoto, Japan).
The procedures for double labeling were followed as described previ-
ously (Mohri et al., 2003). Briefly, in the case of double immunocyto-
chemistry for HPGDS and F4/80, after the primary antibodies had been
applied, the sections were sequentially incubated with Texas Red-
conjugated anti-rat IgG antibody (20 g/ml; ICN, Aurora, OH) and
biotinylated anti-rabbit IgG antibody (20 g/ml; Vector Laboratories),
followed by FITC-conjugated avidin D (20 g/ml; Vector Laboratories).
In the case of double labeling for HPGDS and biotinylated RCA-1, after
incubation with the primary antibody or lectin, the sections were sequen-
tially incubated with the Texas Red-conjugated anti-rabbit IgG antibody
(ICN), followed by FITC-conjugated avidin D. The fluorescence was
examined with an Axiovert 100M microscope connected to a Zeiss
(Oberkochen, Germany) laser-scanning microscope. The frozen sec-
tions, optimal for immunostaining of DP1, were fixed with 100% ethanol
at 20°C for 30 min and then with acetone at room temperature for 5
min. After the sections had been incubated for 5 min with 0.1 M sodium
phosphate, pH 7.4, containing 0.005% saponin (Nakarai Tesque, Kyoto,
Japan) and 20 M (4-amidino-phenyl)-methane-sulfonyl fluoride
(Wako, Osaka, Japan), they were incubated with guinea pig anti-mouse
DP1 antibody. They were then serially reacted with biotinylated anti-
guinea pig antibody (dilution 1:400; Southern Biotechnology, Birming-
ham, AL) and ABC. The reaction using DAB as the chromogen was
enhanced by adding 5 mg/ml nickel (II) ammonium sulfate hexahydrate
(Nakarai Tesque) to the reaction solution. The double immunostaining
for DP1 and F4/80 was performed on unfixed frozen sections as explained
in the paragraph describing the double immunostaining of paraffin
sections.
Terminal deoxynucleotidyl transferase-mediated biotinylated UTP
nick end-labeling (TUNEL) histochemistry combined with immunocy-
tochemistry for -GST was performed as described previously (Taniike
et al., 1999). -GST-positive TUNEL-positive cells were counted in the
cerebral parenchyma of paraffin sections prepared from mice at P45 (n 
4 each).
Primary cultures of mouse microglia and astrocytes. We prepared pri-
mary cultures of microglia and astrocytes from wild-type mouse brains at
P1 and P7, respectively. Cerebral cortices were dissected, and the lepto-
meninges were completely removed. The tissues were minced, suspended
in PBS containing 0.05% trypsin (Invitrogen, Grand Island, NY) and
0.01% DNase I (Sigma, St. Louis, MO), and then incubated for 10 min at
37°C. After incubation and centrifugation, the cell pellets were washed
three times with PBS. The cells were then filtered through a 75 m nylon
mesh, centrifuged, suspended in DMEM (Nakalai Tesque) containing
10% fetal bovine serum (FBS) (JRH Bioscience, Lenexa, KS), 100 IU/ml
penicillin, and 100 g/ml streptomycin (Invitrogen), and transferred to
culture dishes. For microglial cultures, the medium was changed to
DMEM containing 10% FBS after a 24 h culture period. This medium
was exchanged for fresh medium twice weekly thereafter. The superna-
tant including microglial cells was collected and subcultured at 1  10 5
cells per well (six-well plate). After incubation in DMEM without FBS for
6 h, the microglia were treated with A23187 (5 M; Sigma) for 30 min.
When the microglial cells were treated with HQL-79, the inhibitor was
added 15 min before A23187 treatment. The medium after treatment of
the cells with these compounds was measured for its content of PGs.
For astrocyte cultures, the medium was changed to DMEM containing
20% FBS after the initial 24 h culture period. Then, 2 d later, the medium
was changed back to that containing 10% FBS. Once the astrocytes in the
primary culture reached confluence, the cells were rinsed with PBS, sus-
pended in trypsin-containing PBS, and subcultured at 5  10 5 cells per
well (six-well plate). After a 24 h incubation in DMEM containing 1%
FBS, the astrocytes were incubated with BW245C (0.1–100 nM; Cayman
Chemical) or 13, 14-dihydro-15-keto-PGD2 (DK-PGD2) (0.1–100 nM;
Cayman Chemical) for 6 h at 37°C. After the cells had been washed with
PBS, RNA was extracted from them and subjected to quantitative reverse
transcription (RT)-PCR. We confirmed these cells to be either microglia
or astrocytes by their positive immunoreaction with anti-RCA-1 and
F4/80 or GFAP, respectively.
Statistical analysis. Values were expressed as the mean  SE. Data were
analyzed by using the two-tailed t test; values of p  0.05 were considered
to be significant.
Results
HPGDS expression is increased with progression of
demyelination in GALCtwi/twi
First, we measured the levels of PGD2, PGE2, and PGF2 in the
brain of 39-d-old GALCtwi/twi mice (Fig. 1A), in which demyeli-
nation was in progress. The PGD2 content was increased 10-fold
in the GALCtwi/twi brain (35.0  9.0 in GALC/ vs 390.0  32.0
pg/brain in GALCtwi/twi, mean  SE; n  6), whereas the other
PGs did not show such a drastic increase. That is, the PGE2 con-
tent remained the same (20.0  6.0 vs 19.0  12.0), and that of
PGF2 increased only twofold (71.0  13.0 vs 160.0  35.0). At
P39, the HPGDS enzymatic activity was threefold higher in the
GALCtwi/twi cerebrum (0.62  0.05 vs 2.10  0.07
nmol  min1  mg1 protein; n  4) and fivefold higher in the
GALCtwi/twi cerebellum (0.32  0.10 vs 2.30  0.28; n  4) (Fig.
1B). Western blot analysis also revealed that the level of HPGDS
protein in the cerebrum and cerebellum of the GALCtwi/twi brain
at P40 was 2- and 10-fold higher, respectively, than that in the
same brain regions of the GALC/ mice (Fig. 1C).
The level of HPGDS mRNA in the GALC/ brains remained
constant in the cerebrum and gradually decreased in the cerebel-
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lum, whereas it gradually increased in GALCtwi/twi brains after
P30. By P40, the mRNA level in GALCtwi/twi was 4.5-fold higher in
the cerebrum and 16.5-fold higher in the cerebellum than in the
corresponding GALC/ brain regions (Fig. 1D).
Activated microglia/macrophages in GALCtwi/twi strongly
express HPGDS
Immunocytochemical analysis at P40 showed that HPGDS was
localized in resting (ramified) microglia in the GALC/ cerebel-
lum (Fig. 2A, arrows and inset). In the GALCtwi/twi, the level of
HPGDS protein was remarkably increased in activated microglia
(Fig. 2B), which possessed irregular thick processes in the region
of demyelination. Confocal double immunostaining revealed
that 100% of the HPGDS cells were positive for RCA-1 (Fig.
2C), a marker for microglia and endothelial cells (Szumanska et
al., 1987). RCA endothelial cells were negative for HPGDS (Fig.
2C, arrowhead). All cells positive for F4/80, a marker for activated
microglia (Austyn and Gordon, 1981), were also positive for
HPGDS (Fig. 2D, arrows). HPGDS cells were positive for nei-
ther GFAP, a marker for astrocytes, -GST, a marker for OLs, nor
NG2, a marker for OL precursor (data not shown).
DP1 receptor is induced in hypertrophic astrocytes
of GALCtwi/twi
We next quantified the mRNAs of two types of membrane-
bound receptors for PGD2 (i.e., DP1 and DP2 receptors), as well
as the mRNA of PPAR, a nuclear receptor for PGD2 metabolites
(Forman et al., 1995; Kliewer et al., 1995). The DP1 mRNA level
remained constant in the cerebrum and the cerebellum of the
GALC/ mice from P20 through P40 but increased twofold in
the cerebrum of the GALCtwi/twi brains and fourfold in their cer-
ebellum at P40 (Fig. 3A). The expression profile of DP1 mRNA in
the cerebrum and cerebellum in the GALCtwi/twi brain during
development was thus similar to that of HPGDS (Fig. 1C,D). The
contents of DP2 and PPAR mRNAs in the brain were 1⁄10 and
1⁄100, respectively, of the content of DP1 mRNA and did not differ
significantly between GALC/ and GALCtwi/ twi mice at any of
the ages examined (Fig. 3A).
Previous studies have revealed that, in the normal mouse, DP1
receptor immunoreactivity was not detected in the brain except
in the arachnoid trabecular cells of the basal forebrain (Mizogu-
chi et al., 2001). In GALCtwi/twi mice, 100% of DP1-positive cells
in brain parenchyma were GFAP-positive astrocytes, and numer-
ous DP1
 cells were recognized in the HPGDS-rich areas such as
the corpus callosum and cerebellar white matter (CWM) (Fig.
3B) at P40 –P45. The regional distribution profile was almost the
same as that for HPGDS microglia (Fig. 2B). These DP1
receptor-positive cells were identified as hypertrophied astro-
cytes because they possessed large soma with thick-branched pro-
cesses (Fig. 3B, inset) and expressed GFAP as judged by double
immunostaining (Fig. 3C). DP1 receptor-positive cells were not
identical to, but were intermingled with, F4/80 microglia in the
CWM (Fig. 3D), thus suggesting that DP1 receptor-positive as-
trocytes were located close to HPGDS activated microglia.
These results suggest that activated microglia interact with hyper-
trophied astrocytes via PGD2/DP1 signaling in GALC
twi/twi mice.
Cultured microglia produce PGD2 by HPGDS action and
cultured astrocytes upregulate GFAP expression when
stimulated by DP
Using primary cultures of microglia, we investigated whether
these cells produced PGD2 by HPGDS catalysis. As shown in
Figure 4A, after treatment with 5 M A23187, a Ca 2 ionophore,
PGD2 release was increased 23-fold compared with that of con-
trols, whereas PGE2 release was increased only 3.8-fold, and that
of PGF2 remained unchanged. PGD2 production was sup-
pressed dose dependently by treatment with HQL-79, a specific
inhibitor of HPGDS (Matsushita et al., 1998).
To investigate the effect of PGD2 on astrocyte activation, we
determined the contents of DP1 and DP2 receptor mRNAs in
cultured mouse astrocytes before and after stimulation with se-
lective agonists for DP1 [BW245C (Sharif et al., 2000)] and DP2
[DK-PGD2 (Gervais et al., 2001)] (Fig. 4B). Astrocytes in primary
culture contained mRNAs of both DP1 and DP2 receptors in
almost equal amounts. The DP1 receptor mRNA content was
increased after stimulation with either agonist in a dose-
dependent manner from 1 to 100 nM and reached a level 1.5-
fold higher than that without stimulation, whereas the DP2 re-
Figure 1. Increase in PGD2 in GALC
twi/twi brains together with upregulation of HPGDS. A,
Quantities of PGD2, PGE2, and PGF2 in fresh-frozen brains of decapitated GALC
/ (white
columns) and GALCtwi/twi (black columns) mice at P39 were determined by enzyme immunoas-
says. n  6. *p  0.05, **p  0.01. B, HPGDS activity in the cerebrum and cerebellum of
GALC/ (white circles) and GALCtwi/twi (black circles) mice at P39 was determined by using 40
M [1- 14C]PGH2 in the presence of 1 mM glutathione. n  4. *p  0.05, **p  0.01. C,
Western blot analysis of HPGDS and -actin in the brain from GALC/ and GALCtwi/twi. The top
and bottom lanes contained the homogenate (5 g of protein per lane) from the cerebrum and
the cerebellum, respectively. The homogenates of the brain of HPGDS/ mice and of the
oviduct of the wild-type mice were used as the negative and positive control, respectively, of the
HPGDS detection. The graphs on the right show the profiles of HPGDS/-actin amount by
morphometrical analysis of Western blots of GALC/ and GALCtwi/twi at P20, P30, and P40. D,
Quantitative PCR analysis of the contents of mRNAs for HPGDS and G3PDH in GALC/ and
GALCtwi/twi brains was performed by using a LightCycler amplification and detection system.
n  4. Data are mean  SE. *p  0.05, **p  0.01. PND, Postnatal day.
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ceptor mRNA content remained almost unchanged after
stimulation with either agonist. The GFAP mRNA content was
also increased in a dose-dependent manner from 1 to 100 nM after
stimulation with either agonist, becoming twofold higher than
that in the untreated control cultures.
Inhibition of HPGDS/PGD2 /DP1 receptor signaling alleviates
astrogliosis of GALCtwi/twi
To assess the contribution of HPGDS and the DP1 receptor to
astrogliosis in GALCtwi/twi mice, we generated HPGDS/
GALCtwi/twi (supplemental Fig. 1A, available at www.jneuro-
sci.org as supplemental material) and DP1
/GALCtwi/twi (sup-
plemental Fig. 1B, available at www.jneurosci.org as supplemen-
tal material) mice and then compared the mRNA content and the
immunocytochemical profile of GFAP in the brain of these
double-mutant mice at P45 with those of GALCtwi/twi mice. The
content of psychosine, a potent neurotoxin and an accumu-
lated substrate of the missing enzyme galactosylceramidase in
GALCtwi/twi, was not significantly different among GALCtwi/twi,
HPGDS/GALCtwi/twi, and DP1
/GALCtwi/twi in the cerebrum
(8.86  0.45, 8.65  2.47, and 9.07  3.56 ng/mg protein, respec-
tively; n  4) or cerebellum (25.12  2.21, 29.59  4.94, and
35.78  8.98 ng/mg protein, respectively; n  4). Therefore, we
consider the gliotic factors, with respect to the primary metabolic
defect, to be uniform in all strains.
GFAP immunostaining at P45 revealed that only weakly
GFAP astrocytes with thin and delicate processes (Fig. 5A, in-
set) were present in both the cerebrum and cerebellum (Fig.
5A,E) of GALC/ mice. In GALCtwi/twi mice, intensely GFAP
astrocytes with enlarged soma and many
thick processes (Fig. 5B, inset) were nu-
merous and diffusely distributed in both
cerebrum and cerebellum (Fig. 5B,F). In
HPGDS/GALCtwi/twi (Fig. 5C,G) and
DP1
/GALCtwi/twi (Fig. 5D,H) mice, the
GFAP immunoreactivity was slightly
more intense than that in GALC/ mice
but remarkably weaker than that in GAL-
Ctwi/twi mice, and the processes of GFAP
astrocytes were clearly thinner than those
in the GALCtwi/twi mice. The suppression
of astrogliosis was more remarkable in
HPGDS/GALCtwi/twi than in DP1
/
GALCtwi/twi mice. Quantitative RT-PCR
and Northern blot analyses revealed that
the GFAP mRNA content in the cerebel-
lum at P40 was decreased to 15 and 43% of




Furthermore, when we treated
GALCtwi/twi mice with HQL-79, the as-
trogliosis of GALCtwi/twi mice (Fig.
6 A, B) was markedly suppressed in both
the cerebrum (Fig. 6 D) and cerebellum
(Fig. 6 E). DP1 receptor-positive astro-
cytes in the GALCtwi/twi mice (Fig. 6C)
were also decreased in number after the
HQL-79 treatment (Fig. 6 F). Quantita-
tive RT-PCR and Northern blot analyses
(Fig. 6G) revealed that the GFAP mRNA
content in the GALCtwi/twi cerebellum at
P45 was decreased to 29% of the control
by the inhibitor treatment.
Inhibition of HPGDS/PGD2 /DP1 receptor signaling
suppresses apoptosis of OLs and demyelination of GALCtwi/twi
MBP immunostaining revealed that demyelination was severe in
the GALCtwi/twi brain (Fig. 7A), yet myelin was well conserved in
the brains of HPGDS/GALCtwi/twi, DP1
/GALCtwi/twi, and
HQL-79-treated GALCtwi/twi (Fig. 7B–D). Western blotting
analysis for MBP of these mice confirmed the immunocyto-
chemical observation (Fig. 7 E, F ). As shown in Figure 7F, rel-
ative amounts of MBP were significantly retained in the brains
of HPGDS/GALCtwi/twi, DP1
/GALCtwi/twi (n  5), and
HQL-79-treated GALCtwi/twi (n  7) mice. Especially MBPs of
18.5 and 14 kDa, which are expressed in the early phase of
myelination, were better preserved in HPGDS/GALCtwi/twi,
DP1
/GALCtwi/twi and HQL-79-treated GALCtwi/twi than
those of 21.5 and 17 kDa MBPs, expressed in the later phase.
As shown in Figure 7G, the number of -GST-positive
TUNEL-positive cells, which indicate apoptotic OLs, was sig-
nificantly decreased in HPGDS/GALCtwi/twi and HQL-79-
treated GALCtwi/twi (Fig. 7G). To determine whether proin-
flammatory molecule levels were changed in those mice, we
measured the mRNAs for several proinflammatory molecules,
such as iNOS, IL-1, IL-6, and TNF. The level of iNOS, but
not that of IL-1, IL-6, or TNF, was significantly reduced in
HPGDS/GALCtwi/twi and HQL-79-treated GALCtwi/twi ani-
mals (n  4) (Fig. 7H ).
These results indicate that the genetic or pharmacological
blockade of the HPGDS/PGD2/DP1 signaling pathway not only
Figure 2. Upregulation of HPGDS in microglia of GALCtwi/twi brains at P45. A, B, HPGDS immunostaining visualized by using DAB
in the cerebellum of GALC/ (A) and GALCtwi/twi (B). The inset and arrows in A indicate resting HPGDS  microglia. Scale bars: B,
50 m; insets, 10 m. C, D, Confocal images for HPGDS (red in C and green in D) and microglial markers, i.e., RCA-1 (green in C)
and F4/80 (red in D). Arrows in C and D point to HPGDS  microglia, and arrowheads in C point to RCA  HPGDS  endothelial cells,
judged from the morphology. Arrowheads in D indicate HPGDS-positive/F4/80-negative resting microglia. Scale bars: C, D, 10
m.
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suppressed the hypertrophic change in astrocytes or astrogliosis
in GALCtwi/twi mice but also suppressed iNOS expression and
subsequent enhancement of demyelination.
Inhibition of HPGDS/PGD2 /DP1 receptor signaling
diminishes symptomatology of GALCtwi/twi
The lifespan of HPGDS/GALCtwi/twi and DP1
/GALCtwi/twi
mice (47.3  4.5 and 46.2  0.5 d, respectively) was slightly
longer than that of GALCtwi/twi mice (45.5  0.4 d) despite the fact
that the severe peripheral neuropathy, which primarily deter-
mines the lifespan of GALCtwi/twi mice, was observed across all
three groups of mice. The lifespan of HQL-79-treated GALCtwi/twi
mice was significantly longer than that of the vehicle-treated mice
(47.8  1.3 and 44.0  0.7 d, respectively; n  5; p  0.03).
Spasticity and ataxic symptoms of HPGDS/GALCtwi/twi and
DP1
/GALCtwi/twi mice at P45 were remarkably milder than
Figure 3. Induction of DP1 in GALC
twi/twi hypertrophic astrocytes. A, Quantitative PCR anal-
ysis of the contents of mRNAs for DP1, DP2, PPAR, and G3PDH mRNA in GALC
/ (white
circles) and GALCtwi/twi (black circles) brains was performed by using a LightCycler amplification
and detection system. n  4. *p  0.05. PND, Postnatal day. B, DP1 immunostaining in the
GALCtwi/twi cerebellum at P45. DP1
 cells are recognized in the CWM but not in the internal
granular layer (IGL) or Purkinje cell layer (P). Scale bar, 100 m. Inset, High-power view of
DP1
 cells. Scale bar, 10 m. C, Double immunostaining for DP1 (green) and GFAP (red) in
hypertrophied astrocytes. Scale bar, 5 m. D, DP1
 astrocytes (green) and F4/80  microglia
(red) are intermingled in the CWM, although DP1 and F4/80 are not detectable in the same cells.
Scale bar, 10 m.
Figure 4. A, PG production by primary cultures of microglia 30 min after treatment with
A23187 in the absence or presence of HQL-79. After incubation in DMEM without FBS for 6 h, the
microglia were treated with 5 mM A23187 for 30 min. HQL-79 was added 15 min before A23187
treatment. PG contents in the medium were quantified by enzyme immunoassays. White col-
umns, PGD2; gray columns, PGE2; black columns, PGF2. n  3. B, mRNA levels of DP1, DP2, and
GFAP before (gray column) and after stimulation of primary cultures of astrocytes with BW245C
(black columns) or DK-PGD2 (white columns). Once the astrocytes in the primary culture reached
confluence, the cells were rinsed with PBS and subcultured at 5  10 5 cells per well (6-well
plate). After a 24 h incubation in DMEM containing 1% FBS, the astrocytes were incubated with
BW245C (0.1–100 nM) or DK-PGD2 (0.1–100 nM) for 6 h at 37°C. n  3. *p  0.05, **p  0.01.
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those of GALCtwi/twi mice. GALCtwi/twi mice barely staggered with
remarkable intentional tremor, whereas HPGDS/GALCtwi/twi
mice moved about noticeably faster at P45. When suspended by
the tail, HPGDS/GALCtwi/twi animals retained the righting re-
flex, exhibiting a milder tremor (supplemental movie A, available
at www.jneurosci.org as supplemental material). Clinical
symptoms including spasticity and ataxic symptoms were also
milder in HQL-79-treated GALCtwi/twi than in vehicle-treated
GALCtwi/twi mice. HQL-79-treated GALCtwi/twi moved around
smoothly at P45 and retained the righting reflex with milder
tremor when suspended by the tail (supplemental movie B,
available at www.jneurosci.org as supplemental material).
The main cause of the death of GALCtwi/twi mice is peripheral
and cranial nerve palsy, which leads to difficulty in eating and
limits the lifespan. MBP immunostaining (Fig. 7A–D) and elec-
tron microscopy (data not shown) revealed that demyelination
was attenuated in the CNS, but not in the sciatic nerve, of
HPGDS/GALCtwi/twi, DP1
/GALCtwi/twi, and HQL-79-
treated GALCtwi/twi mice. A similar discrepancy between CNS and
PNS has been reported previously in the
case of GALCtwi/twi mice receiving bone-
marrow transplantation (Toyoshima et
al., 1986; Ichioka et al., 1987). Further-
more, Escolar et al. (2005) recently re-
ported that transplantation of umbilical-
cord blood into babies with infantile
Krabbe’s disease resulted in improvement
in the CNS but not in the PNS.
Using immunocytochemistry, we
found that DP1 receptor expression was
upregulated in the CNS but not detected
in the sciatic nerve of GALCtwi/twi (data not
shown), suggesting that PGD2 may not be
involved in progression of the pathology
of the PNS of GALCtwi/twi. This coincides
with a distinction between the CNS and
PNS pathologies in twitcher in which
Schwann cells, unlike OLs, proliferate in
response to demyelination. Furthermore,
apoptotic death does not appear to occur
in the peripheral nerves (Komiyama and
Suzuki, 1992). The demyelination mecha-
nism, therefore, appears to be distinct be-
tween CNS and PNS, particularly regard-
ing the contribution of support cells as
well as PGD2 to the demyelination.
Discussion
PGD2-mediated enhancement of
microglial activation and astrogliosis
during neuroinflammation
Microglia are believed to act primarily as
a line of defense for the brain, because
they express MHC molecules, secrete
proinflammatory cytokines (Wood-
roofe et al., 1991), and produce NO
(Wood et al., 1994) and PGs (Gebicke-
Haerter et al., 1989; Minghetti and Levi,
1995; Bauer et al., 1997). Cyclooxygen-
ases (COXs) are the key enzymes for the
production of PGs and are upregulated
in the CNS in various neurodegenerative
diseases, including Alzheimer’s disease
(Yermakova et al., 1999), Parkinson’s
disease (Teismann et al., 2003), prion disease (Walsh et al.,
2000; Deininger et al., 2003), spinal cord injury (Schwab et al.,
2000), and ischemia (Govoni et al., 2001). Several investiga-
tors have reported selective COX inhibitors to be neuropro-
tective (McGeer and McGeer, 1995; Stewart et al., 1997; Pasi-
netti, 1998; Lim et al., 2000; Govoni et al., 2001), suggesting
that some classes of PGs may play important roles in neuro-
degeneration. Positive immunoreactivities for COX-1 and
COX-2 are mostly observed in microglia (Pasinetti and Aisen,
1998; Yermakova et al., 1999; Walsh et al., 2000). Several re-
ports have demonstrated that microglia produce PGD2 and
PGE2 in vitro (Gebicke-Haerter et al., 1989; Minghetti and
Levi, 1995; Bauer et al., 1997). Between these two prostanoids,
PGE2 has been proposed to act as a mediator in inflammatory
processes (Petrova et al., 1999; Kim et al., 2001) of neurode-
generative diseases such as amyotrophic lateral sclerosis (Il-
zecka, 2003), whereas the direct mechanism of PGD2 involve-
ment in neurodegenerative diseases has not been well studied.
Figure 5. Alleviated astrogliosis in the mutant twitcher lacking HPGDS or DP1 gene. A–H, GFAP immunostaining in the
cerebrum (A–D) and the cerebellum (E–H ) of GALC/ (A, E), GALC twi/twi (B, F ), HPGDS/GALCtwi/twi (C, G), and DP1
/
GALCtwi/twi (D, H ) mice. Insets show higher-magnification view of GFAP-immunoreactive astrocytes for each genotype. Scale bars:
H, 50 m; insets, 5 m. CGL, Cerebellar granular layer; CML, cerebellar molecular layer. I, Quantitative RT-PCR (top) and Northern
blot analyses (bottom) for GFAP and G3PDH in GALC/, GALCtwi/twi, HPGDS/GALCtwi/twi, and DP1
/GALCtwi/twi. The quan-
titative PCR analysis of the contents of mRNAs for GFAP and G3PDH was performed by using a LightCycler amplification and
detection system. For Northern blotting, total RNA (10 g) was electrophoresed in an agarose gel, transferred to nylon mem-
branes, and hybridized with 32P-labeled cDNA probes specific for mouse GFAP and G3PDH. n  3–5. *p  0.05.
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The pathological phenotypes within
the CNS of HPGDS- or DP1-null twitcher
mice are quite different from those seen in
their peripheral immune responses. We
reported previously that DP1
/ mice
used in the ovalbumin-induced asthma
model exhibited a remarkably decreased
accumulation of lymphocytes and proin-
flammatory cytokines in their lungs com-
pared with wild-type mice (Matsuoka et
al., 2000). In contrast, HPGDS/ mice
used in this same model did not show any
changes in the lymphocyte and cytokine
components in their lungs (K. Aritake and
Y. Urade, unpublished results). Together,
these results suggest that the above func-
tional peripheral defect of DP1
/ mice
may not be simply caused by the defi-
ciency of DP1 signaling but may be attrib-
utable to the shunting of PGD2 signaling
to the DP2 pathway. Based on these re-
sults, we believe that the mild gliosis and
demyelination in the HPGDS- and DP1-
null twitcher mice are mainly caused by the
suppression of neuroinflammation around the HPGDS-
expressing microglia and DP1/DP2-possessing astrocytes, al-
though it is possible that decreased cell infiltration into the CNS
in these mice leads to the suppression of secondary gliosis.
We demonstrated here that PGD2 was actively produced in
the GALCtwi/twi brain (Fig. 1A) by HPGDS upregulated in acti-
vated microglia (Figs. 2, 4A). In contrast, the level of PGE2 was
unchanged in the GALCtwi/twi brain when compared with that in
the GALC/ brain (Fig. 1A), and microsomal PGE synthase was
not induced in the GALCtwi/twi brain, as judged from the results of
quantitative RT-PCR and immunocytochemistry (data not
shown). Furthermore, only a small amount of PGE2 release was
observed in cultured microglia after activation (Fig. 4A). There-
fore, PGD2 is thought to play more important roles than PGE2 in
the processes of neuroinflammation that induce microglia acti-
vation and astrogliosis.
In addition, we demonstrated that astrocytes had DP recep-
tors and that PGD2 stimulation accelerated astrogliosis (Figs. 3,
4B). We also showed that inhibition of HPGDS/PGD2/DP1 re-
ceptor signaling by genetic depletion of HPGDS or DP1, or ad-
ministration of HQL-79, reduced astrogliosis and ameliorated
the clinical symptoms of GALCtwi/twi. As shown in Figure 4B,
cultured astrocytes expressed both DP1 and DP2 receptors and
increased GFAP production when stimulated by either a DP1 or
DP2 agonist. This may explain the finding that the astrogliosis of
HPGDS/GALCtwi/twi mice was milder than that of DP1
/
GALCtwi/twi mice, in which PGD2-induced gliosis progressed
in a DP2 receptor-mediated manner. Conversely, in HPGDS
/
GALCtwi/twi mice, PGD2 was not produced in the neuroinflam-
matory loci, signal transduction through both DP1 and DP2 re-
ceptors was blocked, and astrocytic activation was minimal.
In this study, we unexpectedly found that blockade of the
HPGDS/PGD2 signaling resulted in suppressed apoptosis of OLs
(Fig. 7G). This suppression may have contributed to the amelio-
ration of demyelination in HPGDS/GALCtwi/twi and HQL-79-
treated GALCtwi/twi mice. However, DP1
/GALCtwi/twi mice ex-
hibited milder symptoms and their demyelination was clearly
suppressed, as judged from the results of the immunohistochem-
ical and Western blot analyses (Fig. 7C,E,F) compared with the
GALCtwi/twi mice, despite the fact that the number of TUNEL-
positive cells was not significantly decreased (Fig. 7G). Therefore,
secondary demyelination caused by neuroinflammation might
also have been suppressed in the DP1
/GALC twi/twi mice, lead-
ing to decreased spasticity and improved ataxic symptoms.
Predicted mechanism of the HPGDS/PGD2 /DP1 signaling
pathway leading to enhanced astrogliosis and demyelination
Based on the findings described in this present study, we hypoth-
esize the molecular events leading to neuroinflammation in the
GALCtwi/twi brains to be the following (supplemental Fig. 2, avail-
able at www.jneurosci.org as supplemental material). First, mye-
lin and/or OL debris produced by the apoptotic death of OLs in
the GALCtwi/twi brain (Taniike et al., 1999) activates microglia to
synthesize PGD2 through the action of HPGDS. The PGD2 pro-
duced by these activated microglia then stimulates both DP1 and
DP2 receptors on neighboring astrocytes in a paracrine manner
and upregulates the expression of DP1, but not that of DP2, re-
ceptors on these astrocytes. The activation of DP1, a Gs-coupled
receptor (Hirata et al., 1994), increases the intracellular cAMP
level in the astrocytes to induce hypertrophy of these cells. DP2
stimulation also reportedly elevates the intracellular Ca 2 level.
Engagement of DP2, a Gi-coupled receptor (Hirai et al., 2001),
also increases GFAP expression, presumably through elevation of
the intracellular Ca 2 level.
We reported previously that OLs express lipocalin-type PGD
synthase (L-PGDS) but not HPGDS (Taniike et al., 2002). Al-
though L-PGDS and HPGDS catalyze the same reaction to pro-
duce PGD2, these two enzymes have quite different roles within
the context of demyelination. In L-PGDS/GALCtwi/twi, both
OL apoptosis and gliosis were enhanced (Taniike et al., 2002),
unlike the case of HPGDS/GALCtwi/twi, in which gliosis was
ameliorated. Therefore, we hypothesize that L-PGDS localized in
OLs plays a protective role in twitcher mice and that HPGDS,
upregulated in activated microglia, is involved in the secondary
pathology in this disease model.
The instigation of the pathological condition in twitcher is
attributable to the accumulation of psychosine, yet it has been
reported that inflammatory cells and many cytokines are also
involved in the progression of the disease (Wu et al., 2000). Al-
Figure 6. HPGDS-inhibitor alleviated astrogliosis via inhibition of DP1 upregulation in GALC
twi/twi. GALCtwi/twi received a daily
subcutaneous injection of 50 mg  kg 1  d 1 HQL-79 from P25 to P45. As a control, the same volume of vehicle was injected into
GALCtwi/twi during the same period. A–C, Vehicle-treated GALCtwi/twi. D–F, HQL-79-treated GALCtwi/twi. A, B, D, E, GFAP immuno-
staining. C, F, DP1 immunostaining. Scale bar, 50 m. G, Quantitative RT-PCR (top) and Northern blot analyses (bottom) for
vehicle-treated and HQL-79-treated GALCtwi/twi. n  3. *p  0.05. CGL, Cerebellar granular layer; CML, cerebellar molecular layer.
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though the toxicity of psychosine plays a significant role in the
apoptotic death of OLs and in preliminary demyelination, the
ensuing pathology is intensified by cytokines and chemokines
released by activated microglia and possibly by astrocytes as well.
In this sense, the demyelinating process closely resembles that of
pattern III of MS, in which the lesions contain an inflammatory
cell infiltration, activated microglia, and OL apoptosis but with-
out any deposition of Ig and complement (Lucchinetti et al.,
2000). Considering this, along with reports that MHC class II-
null twitcher mice show only mild pathology (Matsushima et al.,
1994) and that inhibiting the proinflammatory cytokine TNF
suppresses demyelination and apoptosis of OLs in GALCtwi/twi
(Kagitani-Shimono et al., 2005), we believe that secondary neu-
roinflammation is a critical component in the progression of the
degenerative condition found in twitcher. Furthermore, because
HPGDS inhibition in GALCtwi/twi significantly suppressed the
disease process, including apoptosis of OLs, it is reasonable to
surmise that neuroinflammation in twitcher mice exacerbates de-
myelination and functional deficits.
Germane to our contention is identify-
ing the physiological role of astrogliosis
within the disease model. Although still a
subject not yet clarified despite intense
discussion, we speculate that hypertrophic
astrocytes may be related to neuroinflam-
mation through their production of cyto-
kines. This study, then, represents the first
example of a PGD2-mediated microglia/
astrocyte interaction in neuroinflamma-
tion. Here, PGD2 was shown to be an im-
portant mediator of neuroinflammation,
and it was demonstrated that the HPGDS
inhibitor HQL-79, an orally active com-
pound remarkably effective at attenuating
neuroinflammation-associated astroglio-
sis, was an able attenuating substance. Our
present results encourage additional study
into both the role of PGD2 in inflamma-
tory and demyelinating diseases as well as
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